Figure 3.

Pulmonary vasodilator therapy preference in pulmonary arterial hypertension (PAH). A, An international cohort of pulmonary vascular disease experts (N = 105) ranked first-line pulmonary vasodilator therapy by preference for the treatment of PAH patients without cardiogenic shock in whom the response to vasoreactivity testing was not established. 1 = most preferred, 5 = least preferred. B, Experts identified the most preferred drug therapy for the first-line treatment of PAH patients with cardiogenic shock. PDE-Vi: phosphodiesterase type 5 inhibitor; ERA: endothelin receptor antagonist; ET_ARA: selective endothelin type A receptor antagonist; PGI₂: prostacyclin analogue.